Galectin Therapeutics Inc. (GALT)

[PaPaGriz]

I read in another forum the patient population used for this study are in stage 1 - 3 progression of NASH. So not necessarily direct competion for GALT. It didn't seem to breakdown improvement in each stage in a way I could figure out.

I didn't quite figure out the improvement in fibrosis. Biopsy showed at least 1% reduction in 23% of the placebo patients vs. the same in 29% of drugged patients. Is that 6% significant in this size of a study?

Big plus for Madrigal is this is an oral delivery method if I read correctly.

Overall this is very good for Madrigal, don't know if it's going to be significant for Galactin or not.